Profile data is unavailable for this security.
About the company
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
- Revenue in USD (TTM)726.44m
- Net income in USD-61.29m
- Incorporated1997
- Employees597.00
- LocationACADIA Pharmaceuticals Inc12830 El Camino Real, Suite 400SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 558-2871
- Fax+1 (858) 558-2872
- Websitehttps://acadia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Incorporated | 482.38m | 106.14m | 2.60bn | 352.00 | 26.26 | 5.11 | 24.28 | 5.39 | 0.9542 | 0.9542 | 4.32 | 4.90 | 0.8007 | 0.9374 | 13.37 | 1,370,384.00 | 17.62 | 21.17 | 20.65 | 23.85 | 98.66 | 98.52 | 22.00 | 27.23 | 4.31 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Hims & Hers Health Inc | 872.00m | -23.55m | 2.62bn | 1.05k | -- | 7.60 | -- | 3.01 | -0.1131 | -0.1131 | 4.17 | 1.61 | 2.16 | 7.13 | 195.17 | 833,652.00 | -5.83 | -- | -7.02 | -- | 81.99 | -- | -2.70 | -- | 2.74 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| CG Oncology Inc | 204.00k | -67.80m | 2.63bn | 61.00 | -- | -- | -- | 12,902.61 | -1.07 | -1.07 | 0.0032 | 2.91 | -- | -- | -- | 3,344.26 | -- | -- | -- | -- | -- | -- | -23,826.96 | -- | -- | -- | 0.002 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Celldex Therapeutics, Inc. | 6.88m | -141.43m | 2.69bn | 160.00 | -- | 5.32 | -- | 391.27 | -2.91 | -2.91 | 0.1421 | 7.68 | 0.0168 | -- | 4.63 | 43,018.75 | -34.56 | -29.65 | -36.80 | -31.42 | -- | -- | -2,054.76 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Neogen Corp | 929.24m | 1.57m | 2.70bn | 2.64k | 1,726.77 | 0.8572 | 22.88 | 2.90 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.40 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
| MoonLake Immunotherapeutics | 0.00 | -36.01m | 2.72bn | 50.00 | -- | 5.19 | -- | -- | -0.7623 | -0.7623 | 0.00 | 8.20 | 0.00 | -- | -- | 0.00 | -14.61 | -- | -16.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Merus NV | 43.95m | -154.94m | 2.79bn | 172.00 | -- | 7.71 | -- | 63.43 | -2.99 | -2.99 | 0.8519 | 6.16 | 0.1056 | -- | 13.56 | 255,505.80 | -37.24 | -29.35 | -45.30 | -35.36 | -- | -- | -352.56 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
| ACADIA Pharmaceuticals Inc | 726.44m | -61.29m | 2.81bn | 597.00 | -- | 6.51 | -- | 3.87 | -0.3774 | -0.3774 | 4.43 | 2.62 | 1.09 | 1.96 | 9.05 | 1,216,812.00 | -9.17 | -27.50 | -12.81 | -32.73 | 94.27 | 95.62 | -8.44 | -38.35 | 2.28 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Arcellx Inc | 110.32m | -70.69m | 2.84bn | 130.00 | -- | 5.74 | -- | 25.74 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Summit Therapeutics Inc | 0.00 | -614.93m | 2.85bn | 105.00 | -- | 36.67 | -- | -- | -1.54 | -1.54 | 0.00 | 0.1107 | 0.00 | -- | -- | 0.00 | -141.83 | -77.32 | -152.22 | -86.35 | -- | -- | -- | -20,989.46 | -- | -110.40 | 0.5628 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Azenta Inc | 641.02m | -17.37m | 2.93bn | 3.50k | -- | 1.20 | 41.94 | 4.57 | -0.2978 | -0.315 | 10.31 | 43.86 | 0.2096 | 2.86 | 3.40 | 183,149.40 | -0.568 | -0.5934 | -0.6169 | -0.6725 | 39.12 | 43.08 | -2.71 | -2.17 | 5.33 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Apogee Therapeutics Inc | 0.00 | -83.99m | 2.94bn | 91.00 | -- | 6.64 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 249.43m | -55.29m | 2.97bn | 497.00 | -- | 8.02 | -- | 11.91 | -1.13 | -1.13 | 4.99 | 7.42 | 0.4439 | 0.3994 | 5.82 | 501,867.20 | -9.84 | -27.55 | -12.51 | -36.82 | 99.58 | -- | -22.17 | -97.12 | 3.77 | -173.40 | 0.1152 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 2.99bn | 525.00 | -- | 16.17 | -- | 16.45 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
Data as of May 02 2024. Currency figures normalised to ACADIA Pharmaceuticals Inc's reporting currency: US Dollar USD
64.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2023 | 42.86m | 26.02% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 13.06m | 7.92% |
| RTW Investments LPas of 31 Dec 2023 | 11.25m | 6.83% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 9.53m | 5.78% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 6.47m | 3.92% |
| EcoR1 Capital, LLCas of 31 Dec 2023 | 5.99m | 3.64% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.27m | 3.20% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 5.00m | 3.03% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 3.75m | 2.28% |
| Weatherbie Capital LLCas of 31 Dec 2023 | 3.04m | 1.84% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
